The IFNGR1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the IFNGR1 gene in the SK-HEP-1 host background. This knockout model provides a loss-of-function platform for interrogating interferon gamma (IFN-??) signaling without introducing defined genetic alterations or clonal selection. The polyclonal nature preserves the genetic heterogeneity of the pool, enabling robust functional studies while avoiding artifacts associated with single-cell isolation. The product is designed for researchers investigating immune regulatory mechanisms, endothelial biology, and cancer immune evasion, offering a ready-to-use tool for downstream phenotypic and molecular analyses.
The parental SK-HEP-1 cell line was originally isolated from the ascites of a patient with adenocarcinoma of unknown origin and exhibits a hybrid phenotype combining endothelial and epithelial characteristics. Functionally, SK-HEP-1 cells model hepatic sinusoidal endothelial-like behavior, including the formation of the hepatic sinusoidal endothelial barrier, support of leukocyte adhesion, and participation in angiogenic processes. Their expression of adhesion molecules and cytokine receptors makes them a valuable model for studying liver-specific endothelial responses, tumor microenvironment interactions, and immune cell trafficking under normal and pathological conditions.
IFNGR1 encodes the ligand-binding alpha subunit of the interferon gamma receptor, which pairs with IFNGR2 to form a functional receptor for the homodimeric cytokine IFN-??. Ligand engagement activates receptor-associated Janus kinases JAK1 and JAK2, leading to phosphorylation, dimerization, and nuclear translocation of the signal transducer and activator of transcription STAT1. Active STAT1 drives transcription of interferon regulatory factor IRF1, the class II transactivator CIITA, and a broad array of interferon-stimulated genes (ISGs), including major histocompatibility complex (MHC) class I and II molecules. This cascade is central to Th1-type immune responses, antigen presentation, and inflammatory signaling. Negative regulation is mediated by suppressors such as SOCS1. By disrupting IFNGR1, the knockout cell population abolishes IFN-??-dependent JAK-STAT signaling, preventing STAT1 phosphorylation and downstream gene induction.
In the context of SK-HEP-1 cells, the IFNGR1 knockout creates a powerful model for dissecting how IFN-?? signaling contributes to the immunological functions of liver sinusoidal endothelium. Loss of IFNGR1 impairs the upregulation of MHC class I and antigen processing machinery, mimicking immune evasion strategies observed in certain liver malignancies and chronic infections. This system also allows investigation of how the sinusoidal barrier modulates leukocyte adhesion and transmigration independently of IFN-??, and how compensatory cytokine pathways may be activated. Given the link between IFNGR1 mutations and Mendelian susceptibility to mycobacterial disease, this model supports research into primary immunodeficiencies and host-defense mechanisms at the hepatic endothelial interface.
The IFNGR1 Knockout SK-HEP-1 Polyclonal Cells are ideally suited for a range of experimental applications, including mechanistic studies of cancer immune evasion, IFN-?? signaling pathway analysis, and hepatic endothelial cell biology. Researchers can employ these cells to assess immunogenicity by measuring MHC class I surface expression via flow cytometry, evaluate STAT1 phosphorylation status by Western blotting following IFN-?? stimulation, or quantify IRF1 and ISG transcript levels through RT-qPCR. Co-culture assays with T cells enable functional evaluation of T-cell-mediated killing, while RNA-seq provides transcriptome-wide insights into pathway disruption. Additional applications include drug response profiling and ELISA-based cytokine quantification. For further information or to inquire about custom solutions, please contact Ascent Research.
